Recombinant vaccinia virus
AssigneePfizer Inc.
InventorsJoseph John Binder, Michael Dale Eisenbraun, Clare Lees, Jeremy Shawn Myers, James Travis Patterson
Life of this patent
Estimating the term…
Abstract
The present disclosure provides human IL-2 variants, recombinant oncolytic viruses comprising the IL-2 variant, compositions comprising the IL-2 variant or recombinant oncolytic virus, and use of the IL-2 variants, recombinant oncolytic virus, or compositions for treating cancer in an individual.
Claims30
An isolated human interleukin 2 (IL-2) variant comprising at least one amino acid substitution as compared to wild-type human IL-2 having the amino acid sequence as shown in SEQ ID NO:
- 1, wherein the IL-2 variant comprises one or more substitutions at amino acid positions selected from the group consisting of:
- a) K35,
- b) both R38 and L40,
- c) both T41 and K43,
- d) both K43 and Y45,
- e) both E62 and K64, and
- f) both L72 and Q74.
3-5. (canceled)
8-14. (canceled)
(canceled)
(canceled)
(canceled)
25-28. (canceled)
(canceled)
(canceled)
39-48. (canceled)
(canceled)
Dependencies are inferred from the claim text.